Popular Articles

Lilly Resubmits Cymbalta(R) Supplemental New Drug Application For Chronic Pain To U.S. Food And Drug Administration
As projected, Eli Lilly and Company (NYSE: LLY) has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA). Lilly"s resubmission is based on a recently completed study in chronic pain due to osteoarthritis, the extension phase of a chronic low back pain study and previously completed studies in pain due to osteoarthritis and chronic low back pain. The application is supported by studies in diabetic peripheral neuropathic pain (DPNP) and fibromyalgia. Buy arimidex to treat cancer.

HHS Purchases Additional H1N1 Vaccine Ingredients
HHS Secretary Kathleen Sebelius announced today that the department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus.

generic viagra online


News of the day
Rise In Computer-Related Injuries
While back pain, blurred vision and mouse-related injuries are now well-documented hazards of long-term computer use, the number of acute injuries connected to computers is rising rapidly. According to a study published in the July 2009 issue of the American Journal of Preventive Medicine, researchers from the Center for Injury Research and Policy and The Research Institute at Nationwide Children"s Hospital; and The Ohio State University College of Medicine, Columbus have found a more-than-sevenfold increase in computer-related injuries due to tripping over computer equipment, head injuries due to computer monitor falls and other physical incidents.
Oncology

Promising New Tool For Fighting Infections

Though it looks like a tiny purple blowtorch, a pencil-sized plume of plasma on the tip of a small probe remains at room temperature as it swiftly dismantles tough bacterial colonies deep inside a human tooth. But it"s not another futuristic product of George Lucas" imagination. It"s the exciting work of USC School of Dentistry and Viterbi School of Engineering researchers looking for new ways to safely fight tenacious biofilm infections in patients - and it could revolutionize many facets of medicine. Two of the study"s authors are Chunqi Jiang, a research assistant professor in the Ming Hsieh Department of Electrical Engineering-Electrophysics, and Parish Sedghizadeh, assistant professor of clinical dentistry and Director of the USC Center for Biofilms. "Nanosecond Pulsed Plasma Dental Probe" appears in the June 2009 issue of Plasma Processes and Polymers. Sedghizadeh explained that biofilms are complex colonies of bacteria suspended in a slimy matrix that grants them added protection from conventional antibiotics. Biofilms are responsible for many hard-to-fight infections in the mouth and elsewhere. But in the study, biofilms cultivated in the root canal of extracted human teeth were easily destroyed with the plasma dental probe, as evidenced by scanning electron microscope images of near-pristine tooth surfaces after plasma treatment. Plasma, the fourth state of matter, consists of electrons, ions, and neutral species and is the most common form found in space, stars, and lightning, Jiang said. But while many natural plasmas are hot, or thermal, the probe developed for the study is a non-thermal, room temperature plasma that"s safe to touch. The researchers placed temperature sensors on the extracted teeth before treatment and found that the temperature of the tooth increased for just five degrees after 10 minutes of exposure to the plasma, Jiang said. The cooler nature of the experimental plasma comes from its pulsed power supply. Instead of employing a steady stream of energy to the probe, the pulsed power supply sends 100-nanosecond pulses of several kilovolts to the probe once every millisecond, with an average power less than 2 Watts, Jiang said. "Atomic oxygen [a single atom of oxygen, instead of the more common O2 molecule] appears to be the antibacterial agent," according to plasma emission spectroscopy obtained during the experiments, she said. Sedghizadeh said the oxygen free radicals might be disrupting the cellular membranes of the biofilms in order to cause their demise and that the plasma plume"s adjustable, fluid reach allowed the disinfection to occur even in the hardest-to-reach areas of the root canal. Given that preliminary research indicates that non-thermal plasma is safe for surrounding tissues, Sedghizadeh said he was optimistic about its future dental and medical uses. Much like the spread of laser technology from research and surgical applications to routine clinical and consumer uses, plasma could change everything; especially since nonthermal plasmas don"t harbor the risks of tissue burns and eye damage that lasers do, he said. "Plasma is the future," Sedghizadeh said. "It"s been used before for other sterilization purposes but not for clinical medical applications, and we hope to be the first to apply it in a clinical setting." "We believe we"re the first team to apply plasma for biofilm disinfection in root canals," Jiang added. "This collaboration is very unique. We"re attacking frontier problems, and we"re happy to be broadening our fields." Beth Dunham University of Southern California


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):